Thematic Pro

ncbi.nlm.nih.gov

Di-valent siRNA-mediated silencing of MSH3 blocks somatic repeat expansion in mouse models of Huntington’s disease - PMC

Molecular Therapy, 2023 · Cited by 7 papers · doi:10.1016/j.ymthe.2023.09.016

Read the original →

What this article backs

• Msh3 Lowering Therapy ↓ Somatic Cag Expansion

• Msh3 Lowering Therapy decreases Somatic Cag Expansion.

In its own words

Di-valent siRNA-mediated silencing of MSH3 blocks somatic repeat expansion in mouse models of Huntington's disease

More from ncbi.nlm.nih.gov

• N

  Elevated plasma and CSF neurofilament light chain concentrations are stabilized in response to mutant huntingtin lowering in the brains of Huntington’s disease mice - PMC

  ncbi.nlm.nih.gov · Jan 1, 2024 High trust

  Backs 1 claim

  • Htt Lowering Therapy ↓ Neurofilament Light

  Read article →
• N

  Neurofilament light protein in CSF and blood is associated with neurodegeneration and disease severity in Huntington’s disease R6/2 mice - PMC

  ncbi.nlm.nih.gov · Jan 1, 2017 High trust

  Backs 1 claim

  • Neurodegeneration ↑ Neurofilament Light

  Read article →